Compare SCYX & INHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCYX | INHD |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 28.1M |
| IPO Year | 2014 | 2023 |
| Metric | SCYX | INHD |
|---|---|---|
| Price | $0.66 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 563.4K | ★ 46.5M |
| Earning Date | 11-05-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,932,000.00 | $2,645,845.00 |
| Revenue This Year | $167.73 | N/A |
| Revenue Next Year | $290.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 787.64 |
| 52 Week Low | $0.57 | $0.12 |
| 52 Week High | $1.49 | $19.78 |
| Indicator | SCYX | INHD |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 19.47 |
| Support Level | $0.65 | $0.12 |
| Resistance Level | $0.72 | $3.45 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 54.91 | 0.99 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.